Fig. 4From: Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patientsPFS and OS. PFS (A) and OS (B) in advanced or metastatic ESCC patients receiving CAM combined with apatinib plus IRTBack to article page